Amniotic fluid embolism: An overview and case report

Mulder, Jay I.

doi:10.1016/s0002-9378(85)80153-8

Cited by 29 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…112–115 However, in the Clark et al’s national registry 19 only 4 of 8 women (50%) had this finding. In addition, the detection of squamous cells in the pulmonary arterial circulation is not pathognomonic for AFE since they have been identified in 21–100% of pregnant women without AFE 116–119 and in non pregnant women. 118,120 Unfortunately, reliable differentiation between maternal and fetal squamous cells is still difficult in the clinical setting.…”

Section: Diagnosismentioning

confidence: 99%

Amniotic fluid embolism: an evidence-based review

Conde-Agudelo

Romero

2009

American Journal of Obstetrics and Gynecology

245

277

View full text Add to dashboard Cite

We conducted an evidence-based review of information bout amniotic fluid embolism (AFE). The estimated incidence of AFE is 1:15,200 and 1:53,800 deliveries in North America and Europe, respectively. The case fatality rate and perinatal mortality associated with AFE are 13–30% and 9–44%, respectively. Risk factors associated with an increased risk of AFE include advanced maternal age, placental abnormalities, operative deliveries, eclampsia, polyhydramnios, cervical lacerations, and uterine rupture. The hemodynamic response in AFE is biphasic, with initial pulmonary hypertension and right ventricular failure, followed by left ventricular failure. Promising therapies include selective pulmonary vasodilators and recombinant activated facto Vlla. Important topics for future research are presented.

show abstract

Section: Diagnosismentioning

confidence: 99%

Amniotic fluid embolism: an evidence-based review

Conde-Agudelo

Romero

2009

American Journal of Obstetrics and Gynecology

245

277

View full text Add to dashboard Cite

show abstract

“…The proportion of AFE in maternal mortality may be 4-6% [11] but AFE is believed to have caused approximately 9% of maternal deaths in the United States from 1968 to 1975 [3] and approximately 10% in UK and Wales from 1979 to 1981 [13]. In the Nordic countries, AFE was the cause of maternal deaths in approximately 4% from 1970 to 1979, being nine cases in a total of 212 maternal deaths [14].…”

Section: Discussionmentioning

confidence: 99%

“…Elements of an embolus may inflict mechanical obstruction of the pulmonary vasculature, cause pulmonary vasospasm, have direct depressant effect on the myocardium, and cause non-cardiogenic pulmonary oedema associated with increased permeability of the alveolar-capillary membrane [3,11,12,[39][40][41][42]. Moreover, it has been suggested that the amniotic fluid can provoke an anaphylaxis or anaphylactoid reaction [2,18,20,[42][43][44][45].…”

Section: Discussionmentioning

confidence: 99%

“…It is relatively rare but is characterised by poor response to treatment and high mortality. In the literature, AFE is usually associated with vigorous spontaneous labour, with hypertonic uterine contractions, or with caesarean section [2][3][4]. Trauma-caused AFE has been described only in individual cases, such as fatal AFE after a blunt abdominal trauma in a motor vehicle accident [5,6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Amniotic fluid embolism as cause of death in a car accident—a case report

Rainio

Penttilä

2003

Forensic Science International

View full text Add to dashboard Cite

“…Studies examining the quality of blood that would be returned to the mother, if cell salvage had been used at caesarean section, have shown that there is no safety concern with modern equipment as amniotic fluid is both effectively and completely removed by cell salvage processing. 27,28 Despite concerns about AFE as a consequence of cell salvage having proven unfounded in research thus far, 27,28 and evidence that the transfer of amniotic fluid into the maternal circulation is a common event that does not necessarily cause adverse effects, [29][30][31][32] this issue remains of concern to clinicians.…”

Section: Cell Salvage In Caesarean Sectionmentioning

confidence: 99%

A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial

Khan

Moore

Wilson

et al. 2018

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 10/57/32. The contractual start date was in October 2012. The draft report began editorial review in December 2016 and was accepted for publication in March 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by t...

show abstract

Amniotic fluid embolism: An overview and case report

Cited by 29 publications

References 7 publications

Amniotic fluid embolism: an evidence-based review

Amniotic fluid embolism: an evidence-based review

Amniotic fluid embolism as cause of death in a car accident—a case report

A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial

Contact Info

Product

Resources

About